Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

1(20.0%)

Early Phase 1

1(20.0%)

5Total

Phase 1(3)

Phase 2(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05783830Early Phase 1Completed

Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856

Role: lead

NCT05416931Phase 2Completed

ACD440 Gel in Peripheral Neuropathic Pain

Role: lead

NCT05077631Phase 1Completed

Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

Role: lead

NCT05077501Phase 1Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856

Role: lead

NCT04704232Phase 1Completed

Study of Safety, Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers

Role: lead

All 5 trials loaded